CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Caribou Biosciences, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $9.34M | $9.51M | $9.48M | $7.61M | $7.44M | $9.23M | $9.27M | $9.72M | $31.35M | $31.65M | $32.77M | $33.96M | 93.1% | +25.5% |
| Rest of world | $694.00K | $1.69M | $1.68M | $1.69M | $1.68M | $693.00K | $724.00K | $1.75M | $1.76M | $1.75M | $1.71M | $653.00K | 6.9% | -58.6% |
From the segment and revenue-disaggregation notes of Caribou Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.